Q1 2025 Vistin Pharma ASA Earnings Call Transcript
Key Points
- Vistin Pharma ASA (LTS:0RAM) reported a revenue increase of 11% year-over-year, reaching NOK115 million for the first quarter of 2025.
- The company's EBITDA rose by 48% compared to the same quarter last year, reaching NOK30 million.
- Sales volume increased by 14% year-over-year, indicating strong demand for their products.
- The company maintains a strong balance sheet with an equity rate of 80% and no interest-paying debts.
- Vistin Pharma ASA has secured a long-term renewable energy supply agreement, ensuring 100% green renewable hydropower until 2032.
- Freight lead times from Asia to Europe remain volatile, potentially impacting supply chain efficiency.
- The company faces challenges with raw material costs due to macroeconomic factors and currency fluctuations.
- Despite strong demand, the company has not yet fully ramped up production capacity on its second manufacturing line.
- The global Metformin prices have declined, affecting the company's pricing strategy.
- The operational cash flow was slightly lower than normal in the first quarter, driven by increased receivables and higher inventory levels.
Good day and thank you for standing by. Welcome to the Visitin Pharma First quarter 2025 report conference call.
(Conference Instructions)
I would now like to hand the conference over to the speaker today, Magnus Tolleshaug. CEO, please go ahead.
Thank you. And welcome to this first quarter presentation of Visitin Pharma. My name is Magnus Tolleshaug. CEO of the company, and with me today I have our CFO, Mr. Alexander Karlsen.
I will now go through the highlights of the quarter. The revenue in the quarter ended at NOK115 million versus NOK104 million in the first quarter of 2024. An increase of 11% our sales volume was up 14% compared to the same quarter last year and we had an increased operational performance with a higher run rate compared to the first quarter last year. The first quarter ended with an EBITDA of NOK30 million compared to NOK20 million in the first quarter of 2024, an increase of 48%.
The EBITDA was positively affected by increased sales
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
